remember when we were down the day after we announced we filed for mTNBC BTD? Why did we go down?
Even when we have phenominal outcomes, we fall. Remember?
Therefore, when we fall, aren't we a bargain at current price? Isn't this a well thought out investment? Shouldn't we buy the dip?
The price fell after good news because the shorts knew, that they can short it for the next week or two or three or a month or two without worrying about another earth shattering announcement that could be made which could wipe them out.
Shorts see only see 3" in front of their faces. The shorts know that nothing will happen in the next few weeks. So they keep driving it down.
We know that as we look down the road, beyond a few months, into the next quarter and the next year, we know we will have a completely different picture. We are getting closer and closer and people are getting excited. But the shorts don't look down the road at all. They look at tomorrow. They look no further than next week. Our outlook is months to years.
Focus on the investment opportunity here. Know exactly why you hold this stock. This will allow you to either sit and hold during a down turn or to buy the dip. Add and don't worry about it. If you study the situation, you know what is going on, don't worry about it. It's gonna work out.
If you don't know why you hold CYDY, then IMO, if you held it, through thick and thin, you will come out on top, but really, if you don't know why you hold CYDY, you should worry, cause the stock will be up and down and make you sick. Eventually, you will get so nauseated that you will puke up your shares at the bottom. You will be so severely shaken out and you will kick yourself so hard when this is at $10 or $20, for being shaken out. The thesis will play out.
In our situation, management is smart in not releasing NASH 700 data without something even more solid and substantial backing it, like a partnership deal along with the awesome data. Remember, NASH 700 is an early trial. It's not a phase III. We need a partner to back us in the next trial. Without that, regardless of how phenominal the results are of that trial, in the end, without a partner, it is only data and the shorts will eat it up.
CytoDyn knows what they are doing.
Even when we have phenominal outcomes, we fall. Remember?
Therefore, when we fall, aren't we a bargain at current price? Isn't this a well thought out investment? Shouldn't we buy the dip?
The price fell after good news because the shorts knew, that they can short it for the next week or two or three or a month or two without worrying about another earth shattering announcement that could be made which could wipe them out.
Shorts see only see 3" in front of their faces. The shorts know that nothing will happen in the next few weeks. So they keep driving it down.
We know that as we look down the road, beyond a few months, into the next quarter and the next year, we know we will have a completely different picture. We are getting closer and closer and people are getting excited. But the shorts don't look down the road at all. They look at tomorrow. They look no further than next week. Our outlook is months to years.
Focus on the investment opportunity here. Know exactly why you hold this stock. This will allow you to either sit and hold during a down turn or to buy the dip. Add and don't worry about it. If you study the situation, you know what is going on, don't worry about it. It's gonna work out.
If you don't know why you hold CYDY, then IMO, if you held it, through thick and thin, you will come out on top, but really, if you don't know why you hold CYDY, you should worry, cause the stock will be up and down and make you sick. Eventually, you will get so nauseated that you will puke up your shares at the bottom. You will be so severely shaken out and you will kick yourself so hard when this is at $10 or $20, for being shaken out. The thesis will play out.
In our situation, management is smart in not releasing NASH 700 data without something even more solid and substantial backing it, like a partnership deal along with the awesome data. Remember, NASH 700 is an early trial. It's not a phase III. We need a partner to back us in the next trial. Without that, regardless of how phenominal the results are of that trial, in the end, without a partner, it is only data and the shorts will eat it up.
CytoDyn knows what they are doing.
9
